13th Annual Biomarkers Congress

Over 300 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions

Over 55 presentations, case studies, novel technologies, round-table and panel discussions focused on the opportunities and challenges of biomarker research discovery and development in a variety of therapeutic areas such as immune-oncology, neuroscience and cardio vascular disease areas, precision medicine, companion diagnostics, data integration methods, and utilising biomarkers in clinical trials

New for 2018 -Workshop taking place on Day 2

“Scientific and Regulatory Considerations for the Analytical Validation of Assays for the Qualification of Biomarkers”

For further information about the workshop and how to register, please click here

6 Interactive Streams:

• Biomarkers in Drug Discovery & Development Therapeutic Areas: Autoimmune, Immuno-oncology, Neuroscience, Oncology
• Precision Medicine, Companion Diagnostics, Molecular Diagnostics Development
• Biomarkers in Drug Discovery & Development Therapeutic Areas: Cardiovascular, Rheumatology, Respiratory, COPD, Rare Diseases, Infectious Diseases, Inherited Diseases
• Innovations in Biomarkers Research, Assay Development, Imaging, Data Integration Methods, Bioinformatics, Trial Design
• Biomarker: Clinical Development & Clinical Trials
• Innovative Biology- NGS & Genomic Markers, Clinical Testing and Diagnostics Development

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities

The co-located 5th Annual Biomarker in Clinical Development Congress provides a great opportunity for attendees to learn more about the latest status updates about the ever-changing regulatory landscape in clinical development, genomic approaches in drug development, RNAseq NGS in biomarker benchmarking and the advances made in NGS techniques in liquid biopsy. Hear the latest challenges and opportunities in the role of biomarkers in clinical development, clinical trials and clinical diagnostics including implementing clinical biomarkers in auto-immune diseases such as cardiovascular, COPD, immuno-oncology, inflammatory and PK/PD biomarkers to clinical biomarkers